

# **CHLORMET TECHNOLOGIES INC.**

**Suite 350 – 409 Granville Street  
Vancouver, BC, V6C 1T2  
Telephone: (604) 678-2531**

**NEWS RELEASE**

**Trading Symbol CSE - PUF**

## **AAA HEIDELBERG INITIATES DOCTOR OUTREACH PROGRAM**

Vancouver, British Columbia (June 23<sup>rd</sup>, 2014) – Chlormet Technologies Inc. (“Chlormet” or the “Company”) (PUF.C) is pleased to announce that AAA Heidelberg has initiated its Doctor Outreach Program. AAA Heidelberg will initially be identifying and then plans on creating relationships with the doctors and clinics in southern Ontario that are pro medical marijuana in advance of the issuance of a MMPR license.

In conjunction with the launch of the Doctor Outreach Program AAA Heidelberg has brought on Mr. David Bard as its Director of Business Development. Mr. Bard will utilize his considerable experience in the pharmaceutical and medical device industry that has given him unique relationships with doctors and clinics in southern Ontario to market AAA Heidelberg and ultimately the various strains of medical marijuana that AAA Heidelberg plans to grow.

David Bard has twenty years of leadership experience in pharmaceutical and medical device marketing, sales, and training. He has worked with leading healthcare companies across North America including AstraZeneca, ALZA, Alcon, GSK and Biovail. During his time with these leaders in the healthcare market he participated in over a dozen successful launches.

Mr. Bard’s specific expertise and passion is in launching new products that involves new product brand management, lifecycle management planning, sales management and product management training. He has commercialization experience in more than twenty therapeutic areas including pain management. As an expert product launch marketer, Mr. Bard has transitioned to consulting for life science companies to assist launch teams in their assessment and preparation of product launches. His company, Bard Consulting Group Inc. was founded to address this gap in the marketplace.

### **About AAA Heidelberg:**

Chlormet Technologies is in the process of purchasing AAA Heidelberg (see news releases dated March 27 and April 2, 2014), a private Ontario company that has an application pending with Health Canada for a new MMPR (Marihuana for Medical Purposes Regulations) license for the production of up to 1,320 pounds of marijuana in the first year. AAA Heidelberg currently owns a secure 8,800 square foot commercial building and land located in London, Ontario.

As a result of the early application, the licensing process is well under way. Upon completion of the interior of the building to the strict guidelines of Heath Canada, which will include four grow

rooms, labs, offices and secure storage for the product, Health Canada will be asked to perform a final inspection to complete the licensing process.

AAA Heidelberg's personnel includes an experienced grow-master who is currently a 'designated grower' under current MMAR licensing. The current crops, that are being grown under the continuing MMAR licensing and are currently thriving due to the injunction against the Health Canada, include ten different strains of marijuana that range from high CBD content to high THC content and are anticipated to be sold for between \$5 to \$15 per gram depending on the strain.

### **About Chlormet Technologies**

Chlormet Technologies Inc. is moving into the Medical Marijuana sector by purchasing a 100% interest in AAA Heidelberg, a private Ontario company that is in the process of applying for a MMPR license.

Chlormet's goal is to become the next publicly traded Canadian company with a medical marijuana production license.

ON BEHALF OF THE BOARD OF DIRECTORS

*"Yari Nieken"*

Interim President and CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.